Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Orphan drugs

EMA hosts meeting to speed up patient access to new drugs

Easier access to medicines for EU citizens has taken a step forward after a first meeting of the European Medicines Agency (EMA) and European Union healthcare payers.

The meeting held on 19 September 2017 was the first step in a bid to streamline drug authorisation decisions across Europe.

The EMA said it hoped collaboration between regulators and healthcare payers, including insurers and health mutual, would help to improve and speed up patients’ access to new treatments, particularly in the challenging field of medicines for rare diseases — orphan medicines.

EMA met representative bodies including the Association Internationale de la Mutualité, the European Social Insurance Platform, the Medicine Evaluation Committee, and the Mechanism of Coordinated Access to Orphan Medicinal Products, a group campaigning for access to products for rare diseases.

Patient access to new medicines in the EU currently begins with marketing authorisation, which is granted following the assessment of the benefits and risks of a medicine by a regulatory authority such as the EMA. Pricing and reimbursement decisions are then adopted by healthcare payers at a national and regional level.

But the EMA said delays can occur in negotiations because drug developer companies focus on the safety, efficacy and quality of a medicine without always providing sufficient evidence around pricing and cost-effectiveness. As a result, more research is needed post-authorisation before a drug can be released to market, thereby slowing down the introduction of new medicines.

EMA executive director Guido Rasi said regulators and payers had an increasingly important role as enablers of medicine development.

“Our co-operation can help medicine developers to address some of the inefficiencies of the current system of clinical research, so that they become better at generating the evidence each of us needs for good decision-making,” he said.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203653

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • European Medicines Agency building

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.